Dee Development Engineers Limited Initial Public Offer to open on June 19, 2024

National, June 12, 2024: Dee Development Engineers Limited (“Dee Piping” or “The Company”), shall open its Bid / Offer in relation to its initial public offer of Equity Shares on Wednesday, June 19, 2024.The total offer size of Equity Shares (face value  ₹ 10 each) comprises of fresh issue aggregating up to  ₹ 3,250 million (The “Fresh Issue”) and offer for sale of up to 45,82,000 Equity Shares. (The “Offer for Sale”). 

This offer includes a reservation of up to aggregating up to  ₹ 10.00 million ( ₹ 1 crore) for subscription by eligible employees. (The “Employee Reservation Portion”). The Anchor Investor Bidding Date shall be Tuesday, June 18, 2024. The Bid/Offer will open on Wednesday, June 19, 2024 for subscription and close on Friday, June 21, 2024. (“Bid Details”) 

The Price Band of the Offer has been fixed at  ₹ 193 to ₹ 203 per Equity Share. Bids can be made for a minimum of 73 Equity Shares and in multiples of 73 Equity Shares thereafter. (The “Price Band”). 

The Company proposes to utilise net proceeds from fresh issue of Equity Shares towards (i) Funding working capital requirements of our Company estimated to ₹ 750 million  in Fiscal 2025; (ii) Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our Company estimated to ₹ 1,750 million in Fiscal 2025; and balance to General corporate purposes (the “Objects of Issue”). 

The offer for sale of up to 45,82,000 Equity Shares (“Offered Shares”) comprising up to 45,82,000 Equity Shares by Krishan Lalit Bansal (collectively, the “Promoter Selling Shareholders”), and such offer for sale of Equity Shares by the Selling Shareholders, “the Offer for Sale”). 

This Equity Shares are being offered through the Red Herring Prospectus of the Company dated June 11, 2024 filed with the Registrar of Companies, National Capital Territory of Delhi and Haryana at New Delhi.  (The “RHP”) 

The Equity Shares to be offered through this Red Herring Prospectus are proposed to be listed on the Stock Exchanges being BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE” together with BSE, the “Stock Exchanges”). For the purposes of the Offer, NSE is the Designated Stock Exchange. (The “Listing Details”). 

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the “SCRR”), read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made in accordance with Regulation 6(1) of the SEBI ICDR Regulations, through the Book Building Process wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (such portion referred to as “QIB Portion”), provided that our Company, in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (the “Anchor Investor Portion”), out of which one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors (“Anchor Investor Allocation Price”), in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) (the “Net QIB Portion”). 

Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs. 

Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors out of which (a) one-third of such portion shall be reserved for applicants with application size of more than ₹0.20 million and up to ₹1.00 million; and (b) two third of such portion shall be reserved for applicants with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Investors. 

And not less than 35% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, Equity Shares will be allotted on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price (net of Employee Discount, if any). All potential Bidders (except Anchor Investors) are required to mandatorily use the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective ASBA accounts, and UPI ID in case of UPI Bidders, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank(s) under the UPI Mechanism, as applicable, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For further details, see ‘Offer Procedure’ on page 451. 

SBI Capital Markets Limited and Equirus Capital Private Limited are the Book Running Lead Managers to the offer (“BRLMs”). All capitalised terms used herein but not defined shall have the same meaning as ascribed to them in the RHP.

 

Comments

Popular posts from this blog

First DPL match was won by US Consulate Staff Team

TATA AIG Strengthens Tamil Nadu Health Insurance Portfolio with New Riders amid Strong Growth

Apollo Cancer Centers now introduces Made in India, CAR T Cell Program